Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6083747

Title:Method of preparing hematopoietic stem cells with gp105-specific antibodies
Inventors:Wong, Peter M. C.; Gladwyne, PA, USA
Chung, Siu-Wah; Gladwyne, PA, USA
Han, Xiaodong; San Francisco, CA, USA
Summary:Described herein are methods of preparing a composition enriched for hematopoietic stem cells which comprise antibodies that bind to the gp 105 protein. Such gp 105-specific antibodies are described as inhibiting the proliferation of BL3 cells that occurs in BL3-conditioned medium (BL3CM) and also inhibiting preferentially the formation of fetal liver cell-derived, multi-lineage colonies in vitro, as well as the development of bone marrow cell-derived, spleen colony-forming unit foci in vivo. Therapeutic applications in the enrichment of hematopoietic stem cells are included.
Abstract:An N-glycosylated glycoprotein, having the molecular weight of 105 kDa when glycosylated and 85 kDa when non-glycosylated, is present on the surface of BL3 hematopoietic stem cells, but is absent from the surfaces of other cells including 32D and FDC-P1 myeloid progenitor cells, EL4 T-cells and 3T3 fibroblasts. Antibody which binds the gp105 protein inhibits the proliferation of BL3 cells that occurs in BL3-conditioned medium (BL3CM). It also can inhibit preferentially the formation of fetal liver cell-derived, multi-lineage colonies in vitro, and the development of bone marrow cell-derived, spleen colony-forming unit foci in vivo. Anti-gp105 antibody can be employed in making a preparation that is enriched for hematopoietic stem cells. Substantially purified from other proteins, the gp105 protein itself is a useful reagent for isolating and characterizing the factor(s) responsible for the proliferative effect of BL3CM.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6083747
Application Number:US1998000114146
Date Filed:13/07/1998
Date Published:04/07/2000
Assignee:Stemcell Therapeutics LLC, Bala Cynwyd, PA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/18/2021